Dingfu Biotarget

Dingfu Biotarget is a clinical-stage biotechnology company headquartered in Suzhou, China, focused on the discovery and development of innovative multi-specific antibody therapeutics for cancer. The company utilizes its proprietary protein engineering platforms to create next-generation T-cell engagers designed to improve efficacy and safety over existing treatments. Its pipeline features several bispecific antibodies, including candidates targeting CD19/CD3 for B-cell malignancies and Claudin 18.2/CD3 for solid tumors. By integrating advanced molecular biology with clinical insights, Dingfu Biotarget aims to provide transformative immunotherapies for patients with refractory or relapsed cancers. The company is backed by prominent venture capital firms and maintains a strong focus on the rapidly evolving oncology landscape in Asia and globally.